Clinical Trial Update: Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carboplatin/etoposide/atezolizumab with or without trilaciclib (G1T28) in extensive-stage small cell lung cancer; results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• Trilaciclib (G1T28) (trilaciclib)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-05-06